Amoy to Develop Companion Diagnostics for AstraZeneca Drugs
publication date: Apr 18, 2022
Amoy Diagnostics, a Shanghai novel molecular diagnostics company, signed a collaboration agreement to develop companion diagnostics for AstraZeneca (LSE/NSDQ: AZN) drugs. The agreement covers development and commercialization. Initially, Amoy will focus on CDx products for genetic variations in patients with prostate or breast cancer. Earlier this month, Amoy announced a similar agreement with HutchMed for a NSCLC diagnostic. Founded in 2008, Amoy claims to be the largest provider of molecular diagnostics products for personalized healthcare in China, as well as a service center for oncology biomarker analysis. More details....
Stock Symbol: (SHZ: 300685)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.